HRP20110049T2 - Opioidi za liječenje nemirnosti kod donjih ekstremiteta - Google Patents

Opioidi za liječenje nemirnosti kod donjih ekstremiteta Download PDF

Info

Publication number
HRP20110049T2
HRP20110049T2 HR20110049A HRP20110049A HRP20110049T2 HR P20110049 T2 HRP20110049 T2 HR P20110049T2 HR 20110049 A HR20110049 A HR 20110049A HR P20110049 A HRP20110049 A HR P20110049A HR P20110049 T2 HRP20110049 T2 HR P20110049T2
Authority
HR
Croatia
Prior art keywords
dosage form
oral dosage
pharmaceutically acceptable
oxycodone
acceptable salt
Prior art date
Application number
HR20110049A
Other languages
English (en)
Croatian (hr)
Inventor
Fleischer Wolfgang
Reimer Karen
Gawora Karin
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of HRP20110049T1 publication Critical patent/HRP20110049T1/xx
Publication of HRP20110049T2 publication Critical patent/HRP20110049T2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Disintegrating Or Milling (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20110049A 2004-06-08 2005-06-01 Opioidi za liječenje nemirnosti kod donjih ekstremiteta HRP20110049T2 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04013469A EP1604667A1 (en) 2004-06-08 2004-06-08 Opioids for the treatment of the restless leg syndrome
PCT/EP2005/005888 WO2005120506A1 (en) 2004-06-08 2005-06-01 Opioids for the treatment of the restless leg syndrome

Publications (2)

Publication Number Publication Date
HRP20110049T1 HRP20110049T1 (en) 2011-02-28
HRP20110049T2 true HRP20110049T2 (hr) 2011-10-31

Family

ID=34925286

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110049A HRP20110049T2 (hr) 2004-06-08 2005-06-01 Opioidi za liječenje nemirnosti kod donjih ekstremiteta

Country Status (25)

Country Link
US (2) US20070185147A1 (OSRAM)
EP (3) EP1604667A1 (OSRAM)
JP (2) JP2008501742A (OSRAM)
KR (2) KR20070037485A (OSRAM)
CN (2) CN103394090A (OSRAM)
AT (1) ATE486603T1 (OSRAM)
AU (1) AU2005251445C1 (OSRAM)
BR (1) BRPI0511300A (OSRAM)
CA (1) CA2569742C (OSRAM)
CY (1) CY1111512T1 (OSRAM)
DE (1) DE602005024571D1 (OSRAM)
DK (1) DK1781291T3 (OSRAM)
ES (1) ES2355247T3 (OSRAM)
HR (1) HRP20110049T2 (OSRAM)
IL (1) IL179896A (OSRAM)
ME (1) ME01238B (OSRAM)
MX (1) MXPA06014391A (OSRAM)
NO (1) NO337890B1 (OSRAM)
NZ (1) NZ552430A (OSRAM)
PL (1) PL1781291T3 (OSRAM)
PT (1) PT1781291E (OSRAM)
RS (1) RS51573B (OSRAM)
SI (1) SI1781291T1 (OSRAM)
WO (1) WO2005120506A1 (OSRAM)
ZA (1) ZA200610477B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773642C (en) 1997-12-22 2006-04-06 Mundipharma Pty Limited Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP2316428A1 (en) 2002-04-05 2011-05-04 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
KR20140141727A (ko) 2009-03-10 2014-12-10 유로-셀티큐 에스.에이. 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
KR101858797B1 (ko) 2010-05-10 2018-05-16 유로-셀티큐 에스.에이. 히드로모르폰 및 날록손을 포함하는 제약 조성물
WO2011141489A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
NZ603170A (en) 2010-05-10 2015-04-24 Euro Celtique Sa Combination of active loaded granules with additional actives
US20180264013A1 (en) * 2010-07-08 2018-09-20 Wellesley Pharmaceuticals, Llc Composition and methods for treating sleep disorders
MX355644B (es) * 2010-08-13 2018-04-26 Euro Celtique S A Star Uso de aglutinantes para fabricar formulaciones estables al almacenamiento.
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
UA116405C2 (uk) 2013-11-13 2018-03-12 Євро-Селтік С.А. Гідроморфон та налоксон для лікування болю та синдрому опіоїдної дисфункції кишечнику

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (OSRAM) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (OSRAM) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
FR2183546B1 (OSRAM) * 1972-05-10 1975-06-20 Servier Lab
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
DK1009387T3 (da) * 1997-07-02 2006-08-14 Euro Celtique Sa Stabiliserede tramadolformuleringer med langvarig frigivelse
BR9813826A (pt) * 1997-12-22 2000-10-10 Euro Celtique Sa Potencial de uso abusivo de administração oral de opióide analgésico
AU773642C (en) * 1997-12-22 2006-04-06 Mundipharma Pty Limited Opioid agonist/antagonist combinations
KR100597517B1 (ko) * 1998-03-27 2006-07-10 파마시아 앤드 업존 캄파니 엘엘씨 카베르골린의 하지 불안 증후군 치료 용도
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en) * 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EA004876B1 (ru) * 2000-02-08 2004-08-26 Эро-Селтик, С.А. Устойчивые к порче композиции опиоидных агонистов для перорального введения
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
IL157932A0 (en) * 2001-04-19 2004-03-28 Warner Lambert Co Fused bicyclic or tricyclic amino acids
CN1525851A (zh) * 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
JP2005515960A (ja) * 2001-05-11 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 乱用耐性のオピオイド投薬形態
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
MXPA04002709A (es) * 2001-09-24 2005-06-06 Johnson & Johnson Derivados articonvulsivos utiles para el tratamiento del sindrome de extremidades inquietas y trastorno periodico del movimiento de extremidades.
EP2316428A1 (en) * 2002-04-05 2011-05-04 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone

Also Published As

Publication number Publication date
AU2005251445B2 (en) 2008-09-04
CA2569742C (en) 2011-03-22
WO2005120506A1 (en) 2005-12-22
CN103394090A (zh) 2013-11-20
PT1781291E (pt) 2011-01-06
EP1781291A1 (en) 2007-05-09
MXPA06014391A (es) 2007-02-19
NZ552430A (en) 2008-09-26
CN1984659A (zh) 2007-06-20
ME01238B (me) 2011-08-31
EP1781291B1 (en) 2010-11-03
EP1604667A1 (en) 2005-12-14
CA2569742A1 (en) 2005-12-22
HRP20110049T1 (en) 2011-02-28
US20120172387A1 (en) 2012-07-05
EP2255808A3 (en) 2011-05-11
IL179896A0 (en) 2007-05-15
US20070185147A1 (en) 2007-08-09
JP2011137020A (ja) 2011-07-14
DE602005024571D1 (de) 2010-12-16
ES2355247T9 (es) 2011-11-03
JP5774865B2 (ja) 2015-09-09
KR20070037485A (ko) 2007-04-04
IL179896A (en) 2013-07-31
RS51573B (sr) 2011-08-31
AU2005251445B8 (en) 2008-09-18
PL1781291T3 (pl) 2011-06-30
ATE486603T1 (de) 2010-11-15
AU2005251445A1 (en) 2005-12-22
DK1781291T3 (da) 2011-02-07
BRPI0511300A (pt) 2007-12-04
NO337890B1 (no) 2016-07-04
SI1781291T1 (sl) 2011-02-28
AU2005251445C1 (en) 2009-04-09
JP2008501742A (ja) 2008-01-24
CY1111512T1 (el) 2015-08-05
EP2255808A2 (en) 2010-12-01
EP1781291B9 (en) 2011-08-31
NO20070113L (no) 2007-03-02
KR20090089921A (ko) 2009-08-24
ZA200610477B (en) 2007-12-27
KR101200869B1 (ko) 2012-11-13
ES2355247T3 (es) 2011-03-24

Similar Documents

Publication Publication Date Title
HRP20110049T2 (hr) Opioidi za liječenje nemirnosti kod donjih ekstremiteta
JP2011137020A5 (OSRAM)
JP2005247859A5 (OSRAM)
AU2009332963B2 (en) Opioid-containing oral pharmaceutical compositions and methods
JP2013151541A5 (OSRAM)
RU2011104146A (ru) Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи
UA93543C2 (ru) Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон
IS7142A (is) Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
RU2013117274A (ru) Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов
HRP20191909T1 (hr) Novi i potentni oblici doze tapentadola
JP2015044834A5 (OSRAM)
JP2004515455A5 (OSRAM)
RU2013136350A (ru) Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист
JP2013540807A5 (OSRAM)
JP2016014040A5 (OSRAM)
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
RU2007149044A (ru) Твердые лекарственные формы наркотических лекарственных средств с улучшенным всасыванием при трансбуккальном введении
AR042463A1 (es) Tratamiento del dolor con combinaciones de nalbufina y agonistas del receptor de opioides kappa y antagosnistas del receptor opioides
HRP20211539T1 (hr) Sublingvalne tablete otporne na zloupotrebu koje sadrže buprenorfin i nalokson
CA2671954A1 (en) Methods for treating or preventing symptoms of hormonal variations
EA200870449A1 (ru) Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
JP2013537915A5 (OSRAM)
JP2011519930A5 (OSRAM)
NZ603170A (en) Combination of active loaded granules with additional actives
NZ603173A (en) Manufacturing of active-free granules and tablets comprising the same